Will quadruplet therapy become the standard induction therapy for newly diagnosed multiple myeloma?
Currently, standard induction therapy in the U.S. for the disease is a triple therapy of lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVd), followed by stem cell transplantation in eligible patients and maintenance therapy with either lenalidomide or bortezomib.
Investigators are now evaluating how the addition of daratumumab (Darzalex), a monoclonal antibody targeting CD38, to triplet therapy can improve outcomes for patients with newly diagnosed myeloma. We want regimens that produce the longest disease-free or progression-free survival, because they predict the best outcomes, including long-term survival, said Rafael Fonseca, MD, chair of the Department of Internal Medicine at the Mayo Clinic in Phoenix. And you do that by achieving the deepest response possible, so getting the deepest response is the most important thing for a frontline regimen at the mom
email article
The advent of next-generation proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies over the last decade has revolutionized the way patients with multiple myeloma are managed.
However, the disease remains challenging, as relapse and disease progression remain common, even after complete remission. Myeloma often mutates and becomes more resistant to subsequent lines of therapy, leading to shorter responses and remissions.
Why CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy is one of the latest available therapeutic strategies in relapsed or refractory multiple myeloma (RRMM). Why is this a promising approach? The bigger question is why CAR T-cell therapy is a good strategy for blood cancer to begin with, said Saad Usmani, MD, of the Levine Cancer Institute in Charlotte, North Carolina.
email article We re not going to get rid of it entirely, globally, so it s a straw-man argument saying it s unachievable. Deepti Gurdasani, PhD, of Queen Mary University of London, on her interpretation of Zero COVID, aiming for elimination, not eradication. It s amazing, and sad, what people will believe, Nicole Baldwin, MD, a pediatrician and target of attacks by the anti-vaxxer community, discussing a Miami school s announcement not to allow vaccinated teachers over concerns of vaccine shedding. I think we simply don t have enough data right now to come to a firm conclusion. Al Ozonoff, PhD, of Harvard Medical School, discussing cases of facial paralysis after mRNA COVID-19 vaccines.